The Johnson & Johnson Janssen vaccine
Stephen Zenner | LightRocket | Getty Images
CDC scientists say their investigation into a rare blood clotting problem related to the Johnson & Johnson Covid-19 vaccine identified 28 people who may have developed life-threatening blockages – three of whom have died.
The Food and Drug Administration and Centers for Disease Control and Prevention urged states on April 13 to temporarily cease use of J & J’s vaccine “out of caution” while examining six women aged 18 to 48 years who developed cerebral venous sinus thrombosis, or CVST combined with low platelets within about two weeks of receiving the shot.
They recommended resuming use of the shot ten days later after the CDC found the benefits of the shots outweighed their risks.
CVST is a type of thrombosis with thrombocytopenia, or TTS, which are blood clots with a low platelet count that are at risk of stroke. Platelets actually help the blood to clot.
CDC official Dr. Tom Shimabukuro said Wednesday that four of the 28 people with TTS were hospitalized on May 7, one of whom was in intensive care, and two were being discharged to a post-acute care facility. The remaining 19 patients have all been discharged, he said during a presentation to the CDC’s Advisory Committee on Immunization Practices. The panel voted earlier in the day to recommend the Pfizer BioNTech vaccine for 12-15 year olds.
The mean age of the patients with TTS was 40 years and ranged from 18 to 59 years. Women between the ages of 30 and 39 formed the greatest risk group. All patients received the J&J shot before the April 13 break. Of the 28 TTS cases, 19 involved the brain, with ten of those patients suffering from cerebral haemorrhage, he said.
The other clots formed in the lower extremities, pulmonary arteries, or other areas of the body.